医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Chlorella Industry Has Acquired FDA GRAS Certification for the Chlorella Powder Product, Unprecedented in Japan for the Exclusively Domestic Cultivation and Production of Chlorella

2022年06月06日 PM06:00
このエントリーをはてなブックマークに追加


 

TOKYO

Chlorella Industry Co., Ltd. (Minato-ku, Tokyo) has acquired FDA GRAS (Generally Recognized As Safe) certification for the chlorella powder product, unprecedented in Japan for the exclusively domestic cultivation and production of chlorella.

Chlorella is a plant-based food source, made up of about 60% protein, and comprised of a variety of vitamins and minerals, chlorophyll and omega-3 fatty acids. In addition, it contains vitamin B12, which is often deficient in vegans and vegetarians.

Having high contents of chlorophyll, Chlorella is used in green food coloring and the prevention of color fading. It is used in various foods such as health foods and supplements, bread and noodles, confectionery, probiotic beverages, smoothies, protein bars, green curry, etc.

About Chlorella Industry Co., Ltd.

Chlorella Industry Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Eiichiro Itanami) was founded in 1964 as the world’s first chlorella manufacturer. We carry out integrated production from cultivation to commercialization of the single-cell green alga Chlorella at the Kyushu Chikugo Factory in Chikugo City, Fukuoka, Japan. We have a wide range of chlorella product lineups including health foods, supplements, additives, agricultural and aquacultural materials. The company motto is “Health and Happiness for Humankind.”
https://www.chlorella.co.jp/en/

View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005438/en/

CONTACT

Chlorella Industry Co., Ltd.

Overseas Business Section

Masaki Iwasaka

Mail: masaki_iwasaka@chlorella.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 《新英格兰医学杂志》发表Fazirsiran治疗α-1抗胰蛋白酶缺乏症患者的二期研究结果
  • Twist Bioscience and Ildong Pharmaceutical Enter into a Collaboration to Enhance Antibody Discovery for Applications in Immuno-oncology
  • 沃博联结束战略评估,决定保留表现优异的博姿业务
  • BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
  • Work for Humankind:联想技术为偏远岛屿开启无限可能